BioMarin Eyes Late 2021 Launch As Achondroplasia Drug Succeeds In Phase III
R&D president Hank Fuchs said vosoritide can be filed based on height gains for children and safety in babies and toddlers with the most common form of dwarfism, but timing depends on meetings with regulators.
You may also be interested in...
BioMarin Pharmaceuticals has raised expectations for its dwarfism product BMN-111 (vosoritide) on the back of strong Phase II data.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.